Just In
- 48 min ago Holi 2024: Pre And Post Skincare Tips To Protect Your Skin During Colourful Festival
- 1 hr ago When Is Total Solar Eclipse 2024? US Authorities Will Close Schools In These States Due To Safety Reasons
- 4 hrs ago Holi 2024: 7 Comfy And Stylish Outfit Ideas To Enjoy The Vibrant Festival
- 5 hrs ago Vastu Tips For Holi: Dos And Don'ts To Follow As Per Vastu Shastra To Invite Positive Energy In Your Home
Don't Miss
- News SBI Mains PO 2023 Final Exam Result Out @sbi.co.in.; Step-By-Step Guide To Check
- Education SBI PO 2023 Final exam result declared; Know how to check
- Movies Bigg Boss Malayalam 6 Voting Results: Rishi Leads With Max Votes; These 3 Contestants In Danger Zone In Week 2
- Sports Moin-ul-Haq Stadium lease as major turning point in Bihar Cricket: BCA President Rakesh Tiwari
- Technology iQOO Neo 9 Pro 128GB Variant Sale on March 21: Most Affordable Snapdragon 8 Gen 2 SoC-Powered Phone in India
- Finance 1:3 Bonus Issue: Multibagger PSU Approves Rs 4.50/Share Dividend; Buy For TP Rs 500-515
- Automobiles Ampere Nexus Electric Scooter Completes K2K Run – Pre-Bookings Open
- Travel Celebrate Lathmar Holi in Nandgaon on March 19: A Colorful Tradition of UP
Zydus Lifesciences Launches Oral Drug Bemdac For Treating Bad Cholesterol
Zydus Lifesciences on Friday said it has launched in India its Bempedoic acid drug under the Bemdac brand for treatment of uncontrolled levels of bad cholesterol.
Bemdac (Bempedoic acid) is a new class of drug which is orally administered and offers a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite lifestyle modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management, the company said in a regulatory filing.
"With Bemdac we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL-c," Zydus Lifesciences Managing Director Sharvil Patel said.
Stating that Bemdac is an important addition to Zydus' portfolio of medicines for managing dyslipidemia and cholesterol, Patel said the mission is to empower patients with a better quality of life through effective disease management and with Bemdac the company has taken a great leap ahead in this endeavour.
The company said LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like a heart attack or stroke.
Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases. Citing various studies, Zydus said, 8 out of 10 Indians are dyslipidemic1 and 112 million adults suffer from high levels of LDL-c; 7 out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c.
Besides this, 5.4 million Indians are found to be intolerant to statin therapy, it added. Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins. This is a huge unmet healthcare need that Bemdac addresses, Zydus claimed.